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Introduction
characteristics of mesenchymal tumours, and because of concurrent local inflammation and 115 necrosis. An incisional biopsy of the primary mass is mandatory to achieve diagnosis (Harvey, 116 1980; Richardson et al., 1983; Hoyt and Withrow, 1984; Vestraete, 2005) . However, some authors 117 argue that, since malignant histological type strongly influences survival, but has a minimal impact 118 on the surgical plan, it may be left up to the clinician to propose whether or not to perform an 119 incisional biopsy. This choice is based on the owner's decision whether or not to treat depending on 120 the prognosis, or on cases where there is doubt regarding the malignancy of the lesion or when 121 treatment modalities other than surgery are preferred (Birchard and Carothers, 1990; Berg, 1998; 122 Liptak and Lascelles, 2012). In earlier studies, oFSA was considered a radioresistant tumour (Todoroff and Brodey, 1979; 217 Harvey, 1980; Thrall, 1981; Richardson et al., 1983; Harvey, 1985; Emms, 1987; Vestraete, 2005) . 218 This was probably due to the limitations that came with orthovoltage radiation machines (Todoroff 219 and Brodey, 1979; Thrall, 1981; Brewer and Turrel, 1982; Creasey and Thrall, 1982) . The 220 combination of orthovoltage radiation with the radiosensitiser misonidazole did not seem to 221 improve the outcome and was associated with side effects (Creasey and Thrall, 1982) . 222 Hyperthermia has also been used together with orthovoltage radiotherapy (Brewer and Turrel, 1982; Nonetheless, the incidence of local recurrence has not improved as much as expected.
315
One year survival 316 The one year survival, regardless of the type of treatment, is reported as 7-76% in studies 317 published before 2000 (Todoroff and Brodey, 1979; Harvey, 1980; Thrall, 1981 ; Brewer and Turrel, Table 1 ). However, when analysing the data by Mann-Whitney U test (Prism v5.0, GraphPad 322 Software), a statistically significant difference was not evident between these two periods (P = 0.23; (Fig. 3) . The difference between the one-year and 333 overall survival could be explained in part by the low number of cases in many of the papers 334 considered, that may have influenced this result. The biology of the tumour, that can be sometimes 335 slow-growing, could also influence the time to progression (both in terms of time to recurrence or 336 metastasis), since it may be longer than one year, thus resulting in a statistically different survival 337 only on the long run. A prospective study enrolling an adequate number of cases followed for at 338 least 2 years would be warranted to clarify this issue. Supplementary Table 1 ) 347 ( Fig. 4) .
348
Recurrence 350
The recurrence rate was 5-87.5% in earlier publications (Todoroff and Brodey, 1979; 351 Harvey et al., 1980; Thrall, 1981; Brewer and Turrel, 1982; Creasey and Thrall, 1982 data, see Appendix: Supplementary Table 1 ). There was no significant difference between time periods (P = 0.40). There was no significant difference between time periods (P = 0.26).
